

# Prof. Dr. med. Reiner WIEST, MD

## Medical Training

- 1988-1995 Medical School, Faculty of Medicine, University of Ulm, Germany
- 1995 German Medical Diploma, University of Ulm and MD Thesis on “Splanchnic hemodynamics during resuscitation”, Experimental Anaesthesiology, University of Ulm, Germany
- 2005 German Internal Medicine Diploma
- 2006 Habilitation Internal Medicine, University Medical School Regensburg (UR) on „Mechanisms of mesenteric vascular hyporeactivity in rat models of portal hypertension”
- 2010 German Gastroenterology Diploma
- 2013 Medical Specialist for specific internal intensive medical care

## Appointments

- 1997-2000 Postdoctoral Research Fellowship, Hepatic Hemodynamic Laboratory Yale University School of Medicine, New Haven, Connecticut, USA
- 2000-2006 Internship and Consultant in Internal Medicine, UR
- 2002 Affiliated Trainee, Liver Unit, Hemodynamic Laboratory, Barcelona
- 2007 Assistant Professor for Experimental/ Clinical Hepatology, UR
- 2008 Head of Clinical Research and Clinical Trials, Internal Medicine, UR
- 2011 Secondo Loco W2-Professor, University Erlangen Affiliated Professor of Medicine, UR
- 2011 Attending Physician (Oberarzt) in Gastroenterology, University Clinic for visceral Surgery and Medicine (UVCM), University Hospital, Bern
- 2013 Senior Physician (Leitender Arzt) in Gastroenterology, University Clinic for visceral Surgery and Medicine (UVCM), University Hospital, Bern
- 2015 Physician-in-Chief (Chefarzt), Gastroenterology, University Clinic for visceral Surgery and Medicine (UVCM), University Hospital, Bern
- Editorial Boards: J.Hepatology, Gut, World J. Gastroenterology  
Frontiers in Medicine, Translational Medicine

### **Selected Honors and Awards:**

- 2000 Lucie-Bolte-Förderpreis
- 2005 Meinhard Classen Program of bavarian association of gastroenterology

## Publications

1.	Publications in international peer-reviewed scientific journals	IF
1	Lang BM, Biedermann L, van Haaften WT, de Vallière C, Schuurmans M, Bègré S, Zeitz J, Scharl M, Turina M, Greuter T, Schreiner P, Heinrich H, Kuntzen T, Vavricka SR, Rogler G, Beerenwinkel N, Misselwitz B; Swiss IBD Cohort Study Group. Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease. <i>Aliment Pharmacol Ther.</i> 2018 Jan;47(1):55-66.	7.286
2	Fernández J, Acevedo J, <b>Wiest R</b> , Gustot T, Amoros A, Deulofeu C, Reverter E, Martínez J, Saliba F, Jalan R, Welzel T, Pavesi M, Hernández-Tejero M, Ginès P, Arroyo V; European Foundation for the Study of Chronic Liver Failure. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. <i>Gut.</i> 2017 Aug 28. pii: gutjnl-2017-314240.	16.658
3	Krautbauer S, Rein-Fischboeck L, Haberl EM, Pohl R, <b>Wiest R</b> , Buechler C. Circulating fibroblast growth factor 21 in patients with liver cirrhosis. <i>Clin Exp Med.</i> 2018 Feb;18(1):63-69.	2.919
4	Krautbauer S, Weiss TS, <b>Wiest R</b> , Schacherer D, Liebisch G, Buechler C. Diagnostic Value of Systemic Cholesteryl Ester/Free Cholesterol Ratio in Hepatocellular Carcinoma. <i>Anticancer Res.</i> 2017 Jul;37(7):3527-3535.	1.937.
5	Krautbauer S, Eisinger K, <b>Wiest R</b> , Liebisch G, Buechler C. Systemic saturated lysophosphatidylcholine is associated with hepatic function in patients with liver cirrhosis. <i>Prostaglandins Other Lipid Mediat.</i> 2016 Jul;124:27-33.	2.640
6	Mikocka-Walus A, Pittet V, Rossel JB, von Känel R; Swiss IBD Cohort Study Group. Symptoms of Depression and Anxiety Are Independently Associated With Clinical Recurrence of Inflammatory Bowel Disease. <i>Clin Gastroenterol Hepatol.</i> 2016 Jun;14(6):829-835.e1	7.398
7	Krautbauer S., <b>Wiest R.</b> , Liebisch G., Buechler Ch. Association of systemic sphingolipids with measures of hepatic function in liver cirrhosis are related to cholesterol. <i>Prostaglandins and Other Lipid Mediators</i> 131, 2017: 25-32	2.64
8	Gutiérrez A, Zapater P, Juanola O, Sempere L, García M, Laveda R, Martínez A, Scharl M, González-Navajas JM, Such J, <b>Wiest R</b> , Rogler G, Francés R. Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease. <i>Am J Gastroenterol.</i> 2016 Apr;111(4):529-40	10.38
9	Meier EM, Pohl R, Rein-Fischboeck L, Schacherer D, Eisinger K, <b>Wiest R</b> , Krautbauer S, Buechler C. Cytokine. Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis 2016 Sep;85:45-50	2.94
10	Mueller R, Ziade F, Pittet V, Fournier N, Ezri J, Schoepfer A, Schibli S, Spalinger J, Braegger C, Nydegger A. <u>Quality of Life in Swiss Paediatric Inflammatory Bowel Disease Patients: Do Patients and Their Parents Experience Disease in the Same Way?</u> <i>Swiss IBD Cohort Study.J Crohns Colitis.</i> 2016 Mar;10(3):269-7 (RW: Co-laborator)	6.59
11	Grønbaek L, Vilstrup H, Deleuran B, <b>Wiest R</b> , Krag A, Jepsen P. Alcoholic Cirrhosis Increases Risk for Autoimmune Diseases: A Nationwide Registry-Based Cohort Study. <i>Clin Gastroenterol Hepatol.</i> 2015 Nov;13(11):2017-22.	7.6
12	Thiele M, Albillos A, Abazi R, <b>Wiest R</b> , Gluud LL, Krag A. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of <u>randomized trials.</u> <i>Liver Int.</i> 2015 Aug;35(8):2009-16	4.47

13	Hartl J, Dietrich P, Moleda L, Müller-Schilling M, <b>Wiest R</b> . <u>Neuropeptide Y restores non-receptor-mediated vasoconstrictive action in superior mesenteric arteries in portal hypertension</u> . Liver Int. 2015 Dec;35(12):2556-63.	4.47
14	Sauerbruch T, Mengel M, Dollinger M, Zipprich A, Rössle M, Panther E, <b>Wiest R</b> , Caca K, Hoffmeister A, Lutz H, Schoo R, Lorenzen H, Trebicka J, Appenrodt B, Schepke M, Fimmers R. Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. German Study Group for Prophylaxis of Variceal Rebleeding. Gastroenterology. 2015 Sep;149(3):660-8	18.19
15	Eisinger K, Krautbauer S, <b>Wiest R</b> , Weiss TS, Buechler C. <u>Reduced serum chemerin in patients with more severe liver cirrhosis</u> . C. Exp Mol Pathol. 2015 Apr; 98(2): 208-1.	2.64
16	Wobser H, <b>Wiest R</b> , Salzberger B, Wohlgemuth WA, Stroszczyński C, Jung EM. <u>Evaluation of treatment response after chemoembolisation (TACE) in hepatocellular carcinoma using real time image fusion of contrast-enhanced ultrasound (CEUS) and computed tomography (CT)--preliminary results</u> . Clin Hemorheol Microcirc. 2014;57(2):191-201	2.24
17	Eisinger K, Krautbauer S, <b>Wiest R</b> , Karrasch T, Hader Y, Scherer MN, Farkas S, Aslanidis C, Buechler C. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. Eur J Clin Invest. 2013 Sep;43(9):926-32.	3.0
18	Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, <b>Wiest R</b> , Reig M, Wagner A, Bolondi; Regorafenib as second-line therapy for intermediate or advanced hepato-cellular carcinoma: Multicentre, open-label, phase II safety study. Eur. J. Cancer 2013 49(16):3412-9.	5.06
19	Dietrich P, Moleda L, Kees F, Müller M, Straub RH, Hellerbrand C, <b>Wiest R</b> . <u>Dysbalance in sympathetic neurotransmitter release and action in cirrhotic rats: Impact of exogenous Neuropeptide Y</u> . J Hepatol. 2013 Feb;58(2):254-61.	9.85
20	Gutiérrez A., Scharl M, Sempere L, Holler E, Zapater P, Almenta I, González-Navajas JM, Such J, <b>Wiest R</b> , Rogler G, Francés R. Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Gut 2014 Feb;63(2):272-80.	10.73
21	M.Thiele, <b>R. Wiest</b> , Gluud LL, Albillos A, Krag A. Can non-selective beta-blocker prevent hepatocellular carcinoma in patients with cirrhosis ? Med. Hypothesis 2013. 81(5):871-4.	1.05
22	Bellot P, Welker MW, Soriano G, Schaewen MV, Appenrodt B, <b>Wiest R</b> , Whittaker S, Tzonev R, Handshiev S, Verslype C, Moench C, Zeuzem S, Sauerbruch T, Guarner C, Schott E, Johnson N, Petrov A, Katzarov K, Nevens F, Zapater P, Such J. Automated Low Flow Pump System for the treatment of Refractory Ascites: a multi-center safety and efficacy study. J Hepatol. 2013 58(5):922-7.	9.85
23	Bruns T, Peter J, Grabe D, Brenmoehl J, Schoelmerich J, <b>Wiest* R</b> , Stallmach* A. Nucleotide-binding oligomerization domain containing 2 (NOD2) gene variants are an risk factor for culture-positive spontaneous bacterial peritonitis and mono-microbial bacterascites (*shared senior authors). Liver International. 2012 Feb;32(2):223-30	3.0
24	Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J; SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012 Apr 15;18(8):2290-300.	7.83
25	Teltschik Z, <b>Wiest R*</b> , Stange E, Wehkamp J. Bacterial translocation is associated with downregulation of Paneth cell antimicrobial peptides in cirrhotic rats. (*: Shared First authorship). Hepatology. 2012 Apr;55(4):1154-63.	10.2

26	Bauer S, Eisinger K, <b>Wiest R</b> , Karrasch T, Scherer Mn, Farkas S, Aslanidis C, Schäffler A, Buechler C. Connective Tissue Growth Factor Level Is Increased In Patients With Liver Cirrhosis Of Different Etiologies But Is Not Associated With Complications Or Extent Of Liver Injury. <i>Regulatory Peptides</i> 2012; 179;10-14	2.1
27	<b>Wiest R</b> , Weigert J, Wanninger J, Neumaier M, Bauer S, Schmidhofer B, Farkas S, Scherer M, Schäffler A, Buechler C. Impaired hepatic clearance of interleukin-6 in patients with liver cirrhosis. <i>Cytokine</i> 2011; 53(2):178-83.	3.1
28	Gutiérrez A, Holler E, Zapater P, Sempere L, Jover R, Pérez-Mateo M, Schoelmerich J, Such J, <b>Wiest R</b> , Francés R. Bacterial DNA modulates human beta-defensin 2 expression in neutrophils of NOD-2/CARD15 wild-type patients with Crohn's disease. <i>Inflamm Bowel Dis.</i> 2011 Aug;17(8):1641-50.	4.97
29	Kirchner G, Scherer M, Obed A, Ruemmele P, <b>Wiest R</b> , Froh M, Loss M, Schlitt HJ, Schoelmerich J, Gelbmann G. Outcome of patients with ischemic-like cholangiopathy with secondary sclerosing cholangitis after liver transplantation. <i>Scand J. Gastroenterology</i> 2011 Apr;46(4):471-8.	1.98
30	Wanninger J; Weigert J; <b>Wiest R</b> ; Bauer S; Karrasch T; Farkas S; Scherer MN; Weiss T; Hellerbrand C; Neumeier M; Schäffler A; Systemic and hepatic vein galectin-3 are increased in patients with alcoholic liver cirrhosis and negatively correlate with liver function. <i>Cytokine</i> 2011 Sep;55(3):435-40.	3.1
31	Wanninger J, Neumeier M, Bauer S, <b>Wiest R</b> , Schmidhofer S, Schäffler A, Aslanidis C, Buechler C. Portal levels of latent transforming growth factor-beta are related to liver function in patients with liver cirrhosis. <i>Eur. J. Gastro.Hepatol</i> 2011; 23: 218-23.	2.08
32	Gäbele E, Dostert K, Hofmann C, <b>Wiest R</b> , Schölmerich J, Hellerbrand C, Obermeier F. Chronic DSS induced colitis enhances bacterial translocation and thereby increases hepatic inflammation and fibrogenesis – a new model of non-alcoholic steatohepatitis. <i>J. Hepatology</i> , 2011. 55 (6): 1391-9.	7.06
33	Moleda L, Trebicka J, Gaebele E, Dietrich P, Sauerbruch T, Hellerbrand C, Straub RH, Schölmerich J, <b>Wiest R</b> . Increased Y1-receptor-mediated vasoconstriction of neuropeptide Y (NPY) in superior mesenteric arteries in CCl <sub>4</sub> -induced cirrhotic rats: mechanism of action and in-vivo effects. <i>Gut</i> 2011 Aug;60(8):1122-32.	9.36
34	Bauer S, Weiss Thomas S, <b>Wiest R</b> ; Schacherer D, Hellerbrand C, Farkas S, Scherer M N, Ritter M, Schmitz G, Schaffler A, Buechler C. Soluble CD163 is not increased in visceral fat and steatotic liver and is even suppressed by free fatty acids in-vitro. <i>Exp Mol Pathol.</i> 2011 91(3):733-739.	2.1
35	Kirovski G, Dorn C, Huber H, Moleda L, Niessen C, Wobser H, Schacherer D, Buechler C, <b>Wiest R</b> , Hellerbrand C. Elevated systemic monocyte chemoattractant protein-1 in hepatic steatosis without significant hepatic inflammation. <i>Exp Mol Pathol.</i> 2011 Dec;91(3):780-3.	2.423
36	Gutiérrez A, Holler E, Zapater P, Sempere L, Jover R, Pérez-Mateo M, Schoelmerich J, Such J., Francés R. Antimicrobial peptide response to blood translocation of bacterial DNA in Crohn's disease is affected by NOD2/CARD15 genotype. <i>Inflamm Bowel Dis.</i> 2011 Aug;17(8):1641-50.	4.525
37	Zorger N, Jung EM, Schreyer AG, Heiss P, Mueller-Wille R, <b>Wiest R</b> , Feuerbach S, Rennert J. Ultrasound-arteriography (US-AP): A new technical approach to perform detection of liver lesions. <i>Clin Hemorheol Microcirc.</i> 2010;46(2-3):117-26.	1.57
38	Dollinger MM, Lautenschlaeger C, Lesske J, Tannapfel A, Wagner AD, Schoppmeyer K, Nehls O, Welker MW, <b>Wiest R</b> , Fleig WE; AIO Hepatobiliary Study Group. Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. <i>BMC Cancer.</i> 2010 Aug 24;10:457.	3.645
39	Riepl B, Grässel S, <b>Wiest R</b> , Fleck M, Straub RH. Tumor necrosis factor and norepinephrine lower the levels of human neutrophil peptides 1-3 secretion by mixed synovial tissue cultures in osteoarthritis and rheumatoid arthritis. <i>Arthritis Res Ther.</i> 2010;12(3):R110.	4.537

40	Krag A, <b>Wiest R</b> , Gluud LL. Fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis. Am J Gastroenterol. 2010 Jun;105(6):1444; author reply 1444-5	9.566*
41	Moleda L, Jurzik L, Froh M, Gäbele E, Hellerbrand C, Straub RH, Schölmerich J, <b>Wiest R</b> . Role of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertension. World J Gastroenterol. 2010 Apr 21;16(15):1837-44.	9.566*
42	Gäbele E, Mühlbauer M, Paulo H, Johann M, Meltzer C, Leidl F, Wodarz N, <b>Wiest R</b> , Schölmerich J, Hellerbrand C. Analysis of monocyte chemotactic protein-1 gene polymorphism in patients with spontaneous bacterial peritonitis. World J Gastroenterol. 2009 Nov 28;15(44):5558-62.	3.176
43	<b>Wiest R</b> , Moleda L, Farkas S, Scherer M, Kopp A, Wönckhaus U, Büchler C, Schölmerich J, Schäffler A. Splanchnic concentrations and postprandial release of visceral adipokines. Metabolism. 2010 May;59(5):664-70	5.777
44	Resch M, <b>Wiest R</b> , Moleda L, Fredersdorf S, Stoelcker B, Schroeder JA, Schölmerich J, Endemann DH. Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertension. Am J Physiol Gastrointest Liver Physiol. 2009 Oct;297(4):G849-57.	2.65
45	Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, <b>Wiest R</b> , Farkas S, Scherer MN, Schäffler A, Aslanidis C, Schölmerich J, Buechler C. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010 Mar;72(3):342-8.	3.327
46	Schacherer D, Girlich C, Jung ME, <b>Wiest R</b> , Scholmerich J. Transabdominal ultrasound with echoenhancement by contrast media in the diagnosis of hepatocellular carcinoma. Dig Dis. 2009;27(2):109-13.	2.875
47	Siroen MP, <b>Wiest R</b> , Richir MC, Teerlink T, Rauwerda JA, Drescher FT, Zorger N, van Leeuwen PA. Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patients. World J Gastroenterol. 2008 Dec 21;14(47):7214-9.	3.176
48	Froh M, Zhong Z, Walbrun P, Lehnert M, Netter S, <b>Wiest R</b> , Conzelmann L, Gabele E, Hellerbrand C, Scholmerich J, Thurman RG. Dietary glycine blunts liver injury after bile duct ligation in rats. World J Gastroenterol. 2008 Oct 21;14(39):5996-6003.	3.176
49	Gäbele E, Mühlbauer M, Dorn C, Weiss TS, Froh M, Schnabl B, <b>Wiest R</b> , Schölmerich J, Obermeier F, Hellerbrand C. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun. 2008 Nov 14;376(2):271-6.	2.466
50	Neugebauer H, Hartmann P, Krenn S, Glück T, Schölmerich J, Straub R, <b>Wiest R</b> . Bacterial translocation increases phagocytic activity of polymorphonuclear leucocytes in portal hypertension: priming independent of liver cirrhosis. Liver Int. 2008 Sep;28(8):1149-57.	4.116
51	<b>Wiest R</b> , Moleda L, Zietz B, Hellerbrand C, Schölmerich J, Straub R. Uncoupling of sympathetic nervous system and hypothalamic-pituitary-adrenal axis in cirrhosis. J Gastroenterol Hepatol. 2008 Dec;23(12):1901-8.	3.452
52	Schepke M, <b>Wiest R</b> , Flacke S, Heller J, Stoffel-Wagner B, Herold T, Ghauri M, Sauerbruch T. Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study. Am J Gastroenterol. 2008 May;103(5):1152-8.	9.566
53	Tacke F, Trautwein C, Yagmur E, Hellerbrand C, <b>Wiest R</b> , Brenner DA, Schnabl B. Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course. J Gastroenterol Hepatol. 2007 Aug;22(8):1256-64.	3.452

54	Froh M, Conzelmann L, Walbrun P, Netter S, <b>Wiest R</b> , Wheeler MD, Lehnert M, Uesugi T, Scholmerich J, Thurman RG. Heme oxygenase-1 overexpression increases liver injury after bile duct ligation in rats. <i>World J Gastroenterol</i> . 2007 Jul 7;13(25):3478-86.	3.176
55	Walbrun P, Hellerbrand C, Weiss TS, Netter S, Neumaier D, Gaebele E, <b>Wiest R</b> , Schoelmerich J, Froh M. Characterization of rat and human Kupffer cells after cryopreservation. <i>Cryobiology</i> . 2007 Apr;54(2):164-72.	1.35
56	<b>Wiest R</b> , Jurzik L, Moleda L, Froh M, Schnabl B, von Hörsten S, Schölmerich J, Straub RH. Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertension. <i>J Hepatol</i> . 2006 Mar;44(3):512-9.	12.486
57	Jurzik L, Froh M, Straub RH, Schölmerich J, <b>Wiest R</b> . Up-regulation of nNOS and associated increase in nitregeric vasodilation in superior mesenteric arteries in pre-hepatic portal hypertension. <i>J Hepatol</i> . 2005 Aug;43(2):258-65.	12.486
58	Hu K, Fink M, Froh M, Gäbele E, Hellerbrand C, Mühlbauer M, <b>Wiest R</b> , Schölmerich J, Schnabl B. Characterization of the human zinc finger protein 267 promoter: essential role of nuclear factor Y. <i>Biochim Biophys Acta</i> . 2005 May 25;1729(1):14-23.	3.66
59	<b>Wiest R</b> , Cadelina G, Milstien S, McCuskey RS, Garcia-Tsao G, Groszmann RJ. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. <i>Hepatology</i> . 2003 Dec;38(6):1508-15.	13.246
60	Hori N, <b>Wiest R</b> , Groszmann RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. <i>Hepatology</i> 1998; 28: 1467-1473	9.50
61	<b>Wiest R</b> , Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. <i>Am J Physiol</i> 1999; 276; 39: G1043-G1051	3.40
62	Shah V, <b>Wiest R</b> , Garcia-Gardena G, Sessa WC, Groszmann RJ. HSP 90 regulation of endothelial nitric oxide synthase contributes to vascular control in portal hypertension. <i>Am J Physiol</i> 1999; 277:G463-G468 (# Shared first authorship)	3.40
63	<b>Wiest R</b> , Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation to mesenteric lymph nodes enhances eNOS-derived NO overproduction in mesenteric vasculature of cirrhotic rats: role for impairment in vascular contractility. <i>J Clin Invest</i> 1999; 104: 1223-1233	14.30
64	<b>Wiest R</b> , Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstriction in splanchnic arteries in portal hypertensive and control rats. <i>Gastroenterology</i> 2001; 120: 975-983	12.70
65	Hellerbrand C, Hartmann A, Richter G, Knöll A, <b>Wiest R</b> , Schölmerich J, Lock G. Hepatocellular Carcinoma in Southern Germany: epidemiological and clinicopathological characteristics and risk factors. <i>Dig Dis</i> 2001; 19: 345-351	1.40
66	<b>Wiest R</b> , Chen F, Cadelina G, Garcia-Tsao G. Effect of lactobacillus acidophilus-fermented diet on intestinal flora and on bacterial translocation in experimental pre-hepatic portal hypertension. <i>Dig Dis</i> 2003; 48: 1136-1141	1.40
<b>2. Reviews/Editorials</b>		
1	Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. <i>J Hepatol</i> . 2017 Nov;67(5):1084-1103.	12.486
2	<b>Wiest R</b> , Lawson M, Geuking M. Pathological Bacterial Translocation in Liver Cirrhosis. <i>J. Hepatol</i> . 201	9.85
3	Gloor B, <b>Wiest R</b> . <u>Pankreaserkrankungen</u> . <i>Ther Umsch</i> . 2016 Nov;73(9):487 (letter)	0.18

4	Stoupis C, Wiest R. Computer- und Magnetresonanztomographie sowie EUS zur Diagnostik von Pankreastumoren. Ther Umsch. 2016 Nov;73(9):489-493.	0.18
5	Benten D, <b>Wiest R</b> . <u>Gut microbiome and intestinal barrier failure - The "Achilles heel" in hepatology?</u> J Hepatol. <b>2012</b> 56(6):1221-3	9.85
6	Schmidt S, <b>Wiest R</b> , Salzberger B, Klebl F. Spontan-bakterielle Peritonitis. Intensiv- und Notfallmedizin <b>2012</b> . 107(7):548-52	0.56
7	<b>Wiest R</b> , A Gerbes. Recent Advances in Clinical Practice: Spontaneous bacterial peritonitis: Guidelines and beyond. Invited. Gut <b>2012</b> . 61(2):297-310	10.73
8	Krag A, <b>Wiest R</b> , Albillos A, Gluud LL, The window hypothesis. Non-hemodynamic effects of non-selective beta-blockers may improve survival in patients with cirrhosis. Gut <b>2012</b> . 61(7):967-9	10.73
9	<b>Wiest R</b> , Lawson M, Geuking M. <u>Reply to: "bacterial translocation in liver cirrhosis: site and role in fibrogenesis"</u> .J Hepatol. <b>2014</b> Sep;61(3):710-1. (letter)	11.34
10	Wiest R, Schoelmerich J. Secondary peritonitis in cirrhosis: "oil in fire". J Hepatol. 2010 Jan;52(1):7-9.	12.486
11	Wiest R. Splanchnic and systemic vasodilation: the experimental models. J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S272-87. Review.	3.328
12	Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology. 2005 Mar;41(3):422-33.	13.246
13	Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):353-72. Review. PubMed PMID: 15123075	3.762
14	Wiest R, Rath HC. Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. Best Pract Res Clin Gastroenterol. 2003 Jun;17(3):397-425.	3.762
15	Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology. 2002 Feb;35(2):478-91.	13.246
<b>3. Case Reports</b>		
1	<b>Wiest R</b> , Tutuiian R, Meier B, Nett P. Use of a cardiac occluder for closure of a complex gastric leak after bariatric surgery.. Endoscopy. <b>2014</b> ;46 Suppl 1 UCTN:E487-8.	6,107.
2	Heimgartner B, Dawson H, De Gottardi A, Wiest R, Niess JH. Successful Treatment of Small Intestinal Bleeding in a Crohn's Patient with Noncirrhotic Portal Hypertension by Transjugular Portosystemic Shunt Placement and Infliximab Treatment. Case Rep Gastroenterol. 2016 Oct 18;10(3):589-595. eCollection 2016 Sep-Dec.	0.97
3	<b>Wiest R</b> , Tutuiian R, Meier B, Nett P. Use of a cardiac occluder for closure of a complex gastric leak after bariatric surgery.. Endoscopy. <b>2014</b> ;46 Suppl 1 UCTN:E487-8.	5.05
4	Hartl J, Ott C, Kirchner G, Salzberger B, Wiest R. Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin. Clin Pract. 2012 Jul 10;2(3):e64.	2.4
5	<b>Wiest R</b> , Glück T, Schönberg J, Schölmerich J, Eilles J, Müller-Ladner U. Clinical image: occult large vessel vasculitis diagnosed by PET image. Rheumatol Int 2001; 20: 250	1.824
<b>4. Conference Contributions</b>		

1	Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. De Francis R. Baveno VI Faculty. J Hepatol. <b>2015</b> Sep;63(3):743-52	10.59
2	<b>Wiest R</b> , EASL International Recognition Awardee 2014: Prof. Guadalupe Garcia-Tsao. J Hepatol. <b>2014</b> Sep;61(3):472-4.	12.486
3	Jalan R, Fernandez J, <b>Wiest R</b> , Schnabl B, Moreau R, Angeli P, Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Burroughs A, Ginès P. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference <b>2013</b> .	
4	<b>Wiest R</b> , S3-Leitlinie "Aszites, SBP und HRS" der DGVS. AG-Leiter und Ko-Koordinator. Konsensus-Konferenz 18.09.2010. Z.Gastroenterologie <b>2011</b> ; 49: 749–779	0.05

## 5. Contributions to Books

1	<b>Wiest R</b> . Bacterial translocation and alterations of the digestive tract. In: Gines P, Arroyo V, Kamath P Hrsg.; Chronic Liver Failure Mechanisms and Management. <b>2017</b>	
2	<b>Wiest R</b> . Kapitel: Leibesumfangszunahme. In: Differentialdiagnose – und –therapie. Ed. Schölmerich J. <b>2017</b>	
3	<b>Wiest R</b> , Chapter: Microbiome and Bacterial Translocation in Liver Cirrhosis. In: Therapeutics in Liver Disease: 10 <sup>th</sup> International Meeting on Therapy in Liver <b>2013</b> . Madrid.	
4	<b>Wiest R</b> , Kapitel: Leberzirrhose und Komplikationen, Aszites, spontan-bakterielle Peritonitis, Ikterus, akutes Leberversagen. In: Praktische Gastroenterologie. Ed. Messmann H. Thieme Verlage <b>2012</b> :	
5	<b>Wiest R</b> . Role of infections for hepatorenal syndrome, Hyponatremia and hepatorenal syndrome. In: Gerbes A Hrsg.; Frontiers in Gastrointestinal Research. Karger; <b>2011</b> : 130-141	
6	<b>Wiest R</b> . Spontaneous bacterial peritonitis. Hyponatremia and hepatorenal syndrome. In: Gerbes A Hrsg.; Frontiers in Gastrointestinal Research. Karger; <b>2011</b> : 65-82	
7	<b>Wiest R</b> . Leberzirrhose und Komplikationen (SBP, portale Hypertension und gastrointestinale Blutung, hepatische Enzephalopathie, Aszites und hepatorenales Syndrom). In: Messmann H. Hrsg.; Praktische Gastroenterologie. Thieme; <b>2011</b> : 610-636	

[https://www.dropbox.com/s/u3ydhfe6reezg3e/Research%20output\\_RW\\_SNF\\_all%2018.7.2018.pdf?dl=0](https://www.dropbox.com/s/u3ydhfe6reezg3e/Research%20output_RW_SNF_all%2018.7.2018.pdf?dl=0)